646 related articles for article (PubMed ID: 28953318)
1. Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
Israelsen M; Krag A; Allegretti AS; Jovani M; Goldin AH; Winter RW; Gluud LL
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011532. PubMed ID: 28953318
[TBL] [Abstract][Full Text] [Related]
2. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.
Allegretti AS; Israelsen M; Krag A; Jovani M; Goldin AH; Schulman AR; Winter RW; Gluud LL
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD005162. PubMed ID: 29943803
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Facciorusso A; Chandar AK; Murad MH; Prokop LJ; Muscatiello N; Kamath PS; Singh S
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
[TBL] [Abstract][Full Text] [Related]
4. Terlipressin for hepatorenal syndrome.
Gluud LL; Christensen K; Christensen E; Krag A
Cochrane Database Syst Rev; 2012 Sep; (9):CD005162. PubMed ID: 22972083
[TBL] [Abstract][Full Text] [Related]
5. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis.
Best LM; Freeman SC; Sutton AJ; Cooper NJ; Tng EL; Csenar M; Hawkins N; Pavlov CS; Davidson BR; Thorburn D; Cowlin M; Milne EJ; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD013103. PubMed ID: 31513287
[TBL] [Abstract][Full Text] [Related]
6. Terlipressin for hepatorenal syndrome.
Gluud LL; Kjaer MS; Christensen E
Cochrane Database Syst Rev; 2006 Oct; (4):CD005162. PubMed ID: 17054242
[TBL] [Abstract][Full Text] [Related]
7. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.
Gifford FJ; Morling JR; Fallowfield JA
Aliment Pharmacol Ther; 2017 Mar; 45(5):593-603. PubMed ID: 28052382
[TBL] [Abstract][Full Text] [Related]
8. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
[TBL] [Abstract][Full Text] [Related]
9. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Goh ET; Stokes CS; Sidhu SS; Vilstrup H; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2018 May; 5(5):CD012410. PubMed ID: 29762873
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
[TBL] [Abstract][Full Text] [Related]
11. Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients.
D'Amico G; Pagliaro L; Pietrosi G; Tarantino I
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD002233. PubMed ID: 20238318
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
Hauser G; Awad T; Brok J; Thorlund K; Štimac D; Mabrouk M; Gluud C; Gluud LL
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005441. PubMed ID: 24585509
[TBL] [Abstract][Full Text] [Related]
13. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Feb; (2):CD001939. PubMed ID: 25715177
[TBL] [Abstract][Full Text] [Related]
14. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.
Nassar Junior AP; Farias AQ; D' Albuquerque LA; Carrilho FJ; Malbouisson LM
PLoS One; 2014; 9(9):e107466. PubMed ID: 25203311
[TBL] [Abstract][Full Text] [Related]
15. Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials.
Sridharan K; Sivaramakrishnan G
J Gen Intern Med; 2018 Jan; 33(1):97-102. PubMed ID: 28924736
[TBL] [Abstract][Full Text] [Related]
16. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.
Wang H; Liu A; Bo W; Feng X; Hu Y
Medicine (Baltimore); 2018 Apr; 97(16):e0431. PubMed ID: 29668606
[TBL] [Abstract][Full Text] [Related]
17. The Comparative Effectiveness of Vasoactive Treatments for Hepatorenal Syndrome: A Systematic Review and Network Meta-Analysis.
Pitre T; Kiflen M; Helmeczi W; Dionne JC; Rewa O; Bagshaw SM; Needham-Nethercott N; Alhazzani W; Zeraatkar D; Rochwerg B
Crit Care Med; 2022 Oct; 50(10):1419-1429. PubMed ID: 35777925
[TBL] [Abstract][Full Text] [Related]
18. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 May; 2016(5):CD003044. PubMed ID: 27153247
[TBL] [Abstract][Full Text] [Related]
19. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2017 May; 5(5):CD001939. PubMed ID: 28518283
[TBL] [Abstract][Full Text] [Related]
20. Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome.
Gonzalez-Garay AG; Serralde-Zúñiga AE; Velasco Hidalgo L; Flores García NC; Aguirre-Salgado MI
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011039. PubMed ID: 38235907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
